ArticleDiseases (Basel, Switzerland)2024
Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2.
Article in Diseases (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 13 citations in OpenAlex.
- Development of attenuated and inactivated Dengue strains using advanced gene editing tools.Molecular biology reports · 2026Review
- Measuring Humoral Immune Responses to SARS-CoV-2: A Comprehensive Review of Serological Assays.Vaccines · 2026Review
- Opportunities and Challenges of mRNA and VLP Technologies for Pan-Flavivirus Vaccine Development: Focus on Conserved Quaternary Epitope Conformations.International journal of molecular sciences · 2026Review
- Associated uncertainty estimation during the validation process of TCIDFrontiers in immunology · 2026Article
- Yellow Fever, an Arboviral Disease with Public Health Impacts: General Aspects and the Use of the One Health Approach in the Context of This Zoonosis.Infection and drug resistance · 2026Review
- SARS-CoV-2 exposure in dogs before and after the largest COVID-19 wave in rural Guatemala, 2022.One health (Amsterdam, Netherlands) · 2025Article
- Evolution of the PRNT: Merging tradition and innovation to set the gold standard in the era of automation.Human vaccines & immunotherapeutics · 2025Review
- Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling.Pathogens (Basel, Switzerland) · 2025Article
- Nanoparticle-supported, rapid, digital quantification of neutralizing antibodies against SARS-CoV-2 variants.Biosensors & bioelectronics · 2025Article
- Household clusters of SARS-CoV-2 Omicron subvariants contemporaneously sequenced from dogs and their owners.mSphere · 2025Article
- Neutralizing and binding antibody dynamics following primary and booster COVID-19 vaccination among healthcare workers.BMC infectious diseases · 2025Observational
- Neutralizing antibody response to different COVID-19 vaccines in Brazil: the impact of previous infection and booster doses.Frontiers in immunology · 2025Article
- Factors influencing antibody response after COVID-19 recombinant protein vaccination in adults: A cross-sectional observational study, in Chongqing, China.Human vaccines & immunotherapeutics · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Massive vaccination positively impacted the SARS-CoV-2 pandemic, being a strategy to increase the titers of neutralizing antibodies (NAbs) in the population. Assessing NAb levels and understanding the kinetics of NAb responses is critical for evaluating immune protection. In this study, we optimized and validated a PRNT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.